Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate

International Angiology

Volumn 27, Issue 5, 2008, Pages 370-376

  Clark, M ^a   Hoppensteadt, D ^a   Walenga, J ^a   Myers, L ^a   Cunanan, J ^a   Jeske, W ^a   Adiguzel, C ^a   Iqbal, O ^a   Fareed J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chondroitin sulfates; Glycosamino glycans; Heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN LYASE;

ANTICOAGULATION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CONTAMINATION; DRUG IMPURITY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; INCIDENCE; MOLECULAR MIMICRY; MOLECULAR TYPING; MOLECULAR WEIGHT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICOAGULANTS; BIOLOGICAL ASSAY; BLOOD COAGULATION; CARTILAGE; CHONDROITIN SULFATES; DRUG CONTAMINATION; ENZYME ACTIVATION; FACTOR XA; HEPARIN; HEPARIN LYASE; HUMANS; MOLECULAR WEIGHT; SWINE;

EID: 56749109796     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Acute allergic-type reactions among patients undergoing hemodialysis-multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008;57:124-125.
2. Information on adverse even reports and heparin. Rockville, MD: Food and Drug Administration, 2008 [Internet] Available from http://www.fda.gov/ cder/drug/infopage/heparin/adverse_events.htm [cited July 22, 2008].
3. Information on heparin sodium injection. Rockville, MD: Food and Drug Administration, 2008 [Internet] Available from http://www.fda.gov/drug/ infopage/heparin/defualt.htm#screening [cited July 22, 2008].
4. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008;6:669-75.
5. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K et al. Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System. N Engl J Med 2008;358:2457-67.
6. Maruyama T, Toida T, Imanari T, Yu G,Linhardt RJ. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 1998;306:35-43.
7. Ahsan A, Jeske W, Hoppensteadt D, Lormeau JC, Wolf H, Fareed J. Molecular profiling and weight determination of heparins and depolymerized heparins. J Pharm Sci 1995;84:724-7.
8. Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987;48: 591-6.
9. Avorn J. Coagulation and Adulteration- building on science and policy lessons from 1905. N Engl J Med 2008;358: 2429-31.
10. Schwartz L. Heparin comes clean. N Engl J Med 2008;358: 2505-9.